AEW541 is primarily investigated for its potential in cancer therapy, particularly in targeting insulin-like growth factor 1 receptor (IGF-1R) signaling pathways. It has shown promise in inhibiting the growth of various cancer cells, including those in breast cancer, sarcoma, and pancreatic cancer, by disrupting the IGF-1R-mediated survival and proliferation mechanisms. Research also explores its use in combination therapies to enhance the efficacy of other anticancer drugs. Additionally, AEW541 is studied for its role in reducing tumor resistance to conventional treatments, making it a candidate for improving therapeutic outcomes in oncology.